It is widely believed that disease using the SARS-CoV-2 disease causes a disproportionate defense response which in turn causes a devastating systemic damage, in people with weight problems particularly, itself a chronic, multi-organ inflammatory disease. weight problems and its own metabolic problems. In the lack of a highly effective vaccine, the restorative potential of immune-modulating medicines can be important, but the advancement of new medicines can be costly and time-consuming. A far more pragmatic solution is always to look for to repurpose existing medicines, particularly the ones that might suppress the heightened cytokine activity observed in obesity, the major risk factor for a Minnelide poor prognosis in COVID-19. Montelukast is a cysteinyl leukotriene receptor antagonist licensed to treat asthma and allergic rhinitis. It has been shown to diminish pulmonary response to antigen, tissue eosinophilia and IL-5 expression in inflammatory cells. It has also been shown to decrease elevated levels of IL-1 and IL8 in humans with viral upper respiratory tract infections compared with placebo-treated patients. In addition, studies have demonstrated a high binding affinity of the montelukast molecule to the terminal site of the viruss main protease enzyme which is needed for virus RNA synthesis and replication. Montelukast, which is cheap, safe and widely available would appear to have the potential to be an ideal candidate drug for clinical trials, particularly in early stage disease before irreparable tissue damage has already occurred. Hypothesis Through a direct anti-viral effect, or by suppression of heightened cytokine release in response to SARS-CoV-2, montelukast will reduce the severity of immune-mediated multiorgan damage resulting from COVID-19, particularly in patients with central obesity and metabolic syndrome. Background It is widely believed that infections using the SARS-CoV-2 pathogen sets off a disproportionate immune system response which in turn causes a damaging systemic damage, particularly in people with weight problems, itself a persistent, multi-organ inflammatory disease. Defense cells accumulate in visceral adipose tissues and as well as paracrine adipocytes to push out a wide variety of biologically energetic cytokines (including IL-1, IL5, IL6 and IL8) that may bring about both regional, pulmonary and systemic irritation , , . A far more intense cytokine surprise is certainly postulated as the system behind the severe immune response observed in serious COVID-19. It really is stunning how harmful the mix of COVID-19 and weight problems is certainly, producing a greater threat of ICU entrance and an increased mortality , recommending the fact that already heightened history inflammatory process caused by Minnelide weight problems might leading the Minnelide disease fighting capability for a far more catastrophic response to SARS-CoV-2 infections. Furthermore, sufferers from a BAME history appear to have got elevated mortality after SARS-CoV-2 infections, an observation which has at least partially been described by the bigger prevalence of central weight problems and its own metabolic complications within this group , . In the lack of a highly effective vaccine, discovering the healing potential of immune-modulating medications is certainly important, but the advancement of new medications is certainly costly and time-consuming. A far more pragmatic solution is always to look for to repurpose existing medications, particularly the ones that might suppress heightened cytokine activity as observed in weight problems, the main risk aspect for an unhealthy prognosis in COVID-19. Montelukast is certainly a cysteinyl leukotriene receptor antagonist certified to take care of asthma and hypersensitive rhinitis. It’s been proven to diminish pulmonary response to antigen, tissues eosinophilia and IL-5 appearance in inflammatory cells . It has additionally been shown to Minnelide diminish elevated degrees of IL-1 and IL8 in human beings with viral higher respiratory tract attacks weighed against placebo-treated sufferers . Furthermore, in silico pc modelling studies have got demonstrated a high binding affinity of the montelukast molecule to the SARS-CoV2 viruss main protease enzyme substrate-binding pocket that is involved in virus RNA synthesis and replication , . Discussion One of the main treatment strategies for COVID-19 is usually to identify new targeted anti-viral drugs based on the genomic information and pathological characteristics of SARS-CoV-2. These drugs are likely to be the most effective against the virus. However, anti-viral drug development and registration is usually time-consuming, the drug might not be available for the current outbreak and it is likely to be very expensive, an important factor particularly in poorer countries afflicted by S5mt COVID-19. An alternative, faster strategy is usually drug repurposing. This relies on identification of potential therapeutic characteristics of drugs currently.